Xeris Pharmaceuticals Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Xeris Pharmaceuticals's estimated annual revenue is currently $2.5M per year.
- Xeris Pharmaceuticals received $10.0M in venture funding in March 2018.
- Xeris Pharmaceuticals's estimated revenue per employee is $14,006
- Xeris Pharmaceuticals's total funding is $237.6M.
- Xeris Pharmaceuticals has 176 Employees.
- Xeris Pharmaceuticals grew their employee count by 47% last year.
- Xeris Pharmaceuticals currently has 3 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Care One Pharma...||$8.4M||42||24%||N/A|
|Firma Clinical ...||$16.7M||83||0%||N/A|
What Is Xeris Pharmaceuticals?
Xeris is a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables. The company's proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of highly concentrated, non-aqueous, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using syringes, auto-injectors, multi-dose pens, and infusion pumps. Xeris platforms have the potential to offer distinct advantages over existing formulations of marketed and development-stage products. In particular, XeriSol and XeriJect offer the opportunity to eliminate reconstitution, enable long-term room temperature stability, significantly reduce injection volume, and eliminate the requirement for intravenous (IV) infusion. These attributes can lead to products that are easier to use by patients, caregivers, and health practitioners and reduce costs for payers and the healthcare systemkeywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Solar Power
Number of Employees
Employee Growth %
|Paul Edick||Chairman And Ceo|
|John Shannon||Chief Operating Officer|
|Allison Wey||Senior Vice President, Investor Relations & Corporate Communications|
|Ed Drower||Director Quality|
|Mike Davis||Director, Quality Control|
|Chelsea Boundy||Senior Manager, Regulatory Operations|
|Aziz Alam||Senior Director, Global Regulatory Affairs|
|Ashley Gregory||Corporate Training Manager|
|John T. Mathis||Regional Medical Affairs Director||Email Available|
|Rondell Wills||Territory Business Manager|
Xeris Pharmaceuticals News
After a three-month PDUFA extension, Xeris Pharmaceuticals and XERS investors are preparing for Gvoke's new PDUFA date on September ...
So shareholders might well want to know whether insiders have been buying or selling shares in Xeris Pharmaceuticals, Inc. (NASDAQ:XERS).
Xeris Pharma's Gvoke is a stable and ready to use glucagon self-injector therapy. It has shown non-inferiority to Lilly and Novo Nordisk ...
Xeris Pharmaceuticals Funding
|2011-12-13||$1.5M||A||Central Texas Angel Network||Article|
|2018-03-09||$45.0M||Undisclosed||Silicon Valley Bank||Article|
Xeris Pharmaceuticals Executive Hires